SOHO 2022 - Annual Meeting of the Society of Hematologic Oncology
Sep 28 - Oct 01, 2022 | HoustonTXUS
LARVOL is not affiliated with Annual Meeting of the Society of Hematologic Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 128 abstracts linked to Trials
Updated Results from the Phase II Study of Blinatumomab in Combination with Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Rusfertide (Ptg-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera
Orca-T, A Precision Engineered Allograft, Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies
A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfi t/Frail Patients With Diffuse Large B-Cell Lymphoma (LOTIS-9)
AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation
Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study
First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study
The Impact of Post-Remission Granulocyte Colony-Stimulating Factor (G-CSF) Use (G-CSFu) in the Phase 3 Studies of Venetoclax (Ven) Combination Treatments in Patients (Pts) With Newly Diagnosed Acute Myeloid Leukemia (AML)
Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results
Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
Community Versus Academic Practice in Essential Thrombocythemia and Myelofi brosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden: Analysis of Data from the MOST Study
Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfi lzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma
Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3– Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofi brosis — JAK Inhibitor- Naïve or With Suboptimal Response to Ruxolitinib — Preliminary Data From the MANIFEST Study